Anthropic launches Claude Science and says it plans to develop drugs

In short: Anthropic unveiled Claude Science for researchers and said it plans to develop drugs itself, starting with treatments for neglected diseases.

What happened

Anthropic announced a new product called Claude Science at an event titled “The Briefing: AI for Science.” The company describes it as an “AI workbench for scientists,” meaning a single place where researchers can bring together scattered tools and data, and create charts and visuals.

At the same event, Anthropic said it wants to develop drugs of its own. Eric Kauderer-Abrams, Anthropic’s head of life sciences, said the company will focus on “neglected” diseases, which usually means illnesses that get less attention and funding.

Anthropic has not shared many specifics. According to reporting in The Verge, the company did not say what it would do if it finds a promising drug candidate, for example whether it would run lab work, animal testing, human trials, or manufacturing on its own or with partners.

Why it matters

More AI companies are trying to sell tools to drug makers and researchers, but Anthropic’s plan is a more direct step. It could put the company in an unusual spot, selling software to pharmaceutical companies while also trying to make its own drugs.

Experts also cautioned that using AI in drug research does not mean medicines will reach patients quickly. AI can help generate ideas, like suggesting new molecules to test (think of it as a fast brainstorming helper), but real-world experiments and clinical trials still take years, cost a lot of money, and often fail. No drug described as “AI-designed” has yet made it all the way through clinical trials and approval to reach the market.

Source: The Verge AI